Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
martedì, ottobre 20
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Cartesian Therapeutics Inc
RNAC
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$6.08
-0.19
-3.03%
Ult. Agg.: Oct 19, 4:00 PM
$6.08
-0.19
-3.03%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Cartesian Therapeutics Financials
Cartesian Therapeutics (RNAC) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Cartesian Therapeutics Q2 EPS $0.46 Beats $(0.86) Estimate
Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly earnings of $0.46 per share which beat the analyst consensus estimate of $(0.86) by 153.49 percent. This is a 8 percent decrease over earnings of $0.50 per share
Benzinga Newsdesk
PRO
Cartesian Therapeutics Q1 EPS $(1.46) Misses $(0.88) Estimate, Sales $78.000K Miss $99.833K Estimate
Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly losses of $(1.46) per share which missed the analyst consensus estimate of $(0.88) by 65.91 percent. This is a 114.71 percent decrease over losses of $(0.68) per
Benzinga Newsdesk
PRO
CORRECTION: Cartesian Therapeutics Q4 Adj. EPS $(1.39) Misses $(0.85) Estimate, Sales $947.00K Beat $94.67K Estimate. Adj. EPS excludes Impairment Charges Of $56.7M
Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly losses of $(1.39) per share which missed the analyst consensus estimate of $(0.85) by 62.95 percent. This is a 247.5 percent decrease over losses of $(0.40) per
Benzinga Newsdesk
Insights into Cartesian Therapeutics Q4 Earnings
Benzinga Insights
PRO
Cartesian Therapeutics Q3 EPS $(1.38) Misses $(0.84) Estimate, Sales $452.000K Beat $243.500K Estimate
Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly losses of $(1.38) per share which missed the analyst consensus estimate of $(0.84) by 63.31 percent. This is a 22.12 percent decrease over losses of $(1.13) per
Benzinga Newsdesk
PRO
Cartesian Therapeutics Q2 EPS $0.50 Compared With $0.54 YoY, Sales Total $298.000K
Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly earnings of $0.50 per share which beat the analyst consensus estimate of $(0.82) by 160.98 percent. This is a 7.41 percent decrease over earnings of $0.54 per share
Benzinga Newsdesk
